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In November 2013, President Barack Obama signed the Drug Quality and Security Act, aimed at regu-
lating compounding pharmacies and establishing a 
track-and-trace pedigree system for drugs. The law 
falls short of the mark on both 
counts. The new Food and Drug 
Administration (FDA) license for 
sterile drug compounders is en-
tirely voluntary, and the track-and-
trace requirement will be phased 
in over a decade, preempting a 
California law that would have tak-
en effect many years earlier.
Compounding gained unwel-
come attention after the 2012 
fungal meningitis outbreak that 
was linked to the New England 
Compounding Center (NECC) in 
Framingham, Massachusetts. The 
Centers for Disease Control and 
Prevention (CDC) has now identi-
fied 751 confirmed or probable 
cases of fungal meningitis in 
20 states, including 64 deaths in 
9 states. Over the past year, beefed-
up state and FDA inspections have 
uncovered substantial lapses at 
many large compounding phar-
macies throughout the country.
The states with the largest 
death tolls from fungal menin-
gitis did not routinely inspect 
out-of-state compounders, relying 
instead on pharmacies’ home-state 
regulators. And it would not have 
been practical for inspectors from 
all 23 states receiving compounded 
drugs from the NECC to physi-
cally travel to Framingham for 
annual inspections. When states 
noticed problems with NECC 
products, coordination was lack-
ing. In April 2011, Colorado filed 
a cease-and-desist order against 
the NECC, blocking sales in the 
state.1 No fungal meningitis cas-
es have been reported in Colora-
do, which speaks well of its reg-
ulators. But the Colorado order 
did not lead to quick action in 
other states, despite the fact that 
Colorado gave notice to both 
Massachusetts and the FDA. When 
compounders ship to dozens of 
states, no single state is in a po-
sition to adequately regulate.
Congress had responded once 
before, in 1997, with the passage 
of Section 503A of the Federal 
Food, Drug, and Cosmetic Act. 
Section 503A created a safe har-
bor for traditional local com-
pounding pharmacies, exempting 
them from further FDA regula-
tion. Congress distinguished tra-
ditional compounding from man-
ufacturing on the basis of several 
features drawn from previous 
guidance documents, including 
whether the drug was advertised 
or promoted. In Thompson v. West-
ern States Medical Center (2002), the 
Supreme Court struck down the 
provision prohibiting the adver-
tising of compounded drugs, de-
ciding that it violated the First 
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Amendment. After that decision, 
the scope of the FDA’s remain-
ing authority under Section 503A 
was unclear.2
The Drug Quality and Security 
Act reenacts Section 503A with 
the advertising provisions re-
moved. Traditional compounders 
can now operate without fear of 
federal enforcement. By infer-
ence, the FDA now has stronger 
authority to proceed against any 
compounder that exceeds the 
limits of Section 503A. These 
rules have been on the books 
since 1997 but have never been 
enforced, because of the Western 
States litigation. Now, after more 
than 16 years, the FDA can use 
Section 503A.
The more disappointing provi-
sion of the new law is found in 
Section 503B, which creates an 
optional new license for sterile 
compounders, to be known as 
“outsourcing facilities.” This new 
license applies tougher standards 
than those applied to traditional 
compounders but is less stringent 
than the full rules applied to 
drug manufacturers. In the Sen-
ate bill, the outsourcing-facility 
license was mandatory, but the 
final act followed the House bill, 
making the license entirely vol-
untary. Over the past year, most 
of the debate in Congress has 
centered on how to draw the line 
between traditional compound-
ing and activities that require the 
new license. The legislative com-
promise leaves that choice up to 
the compounder.
Few compounders will eagerly 
embrace the new license. Out-
sourcing facilities are subject to 
higher expenses than traditional 
compounders. They must comply 
with current Good Manufactur-
ing Practices and, for the first 
time, report serious adverse events 
that occur with compounded 
drugs. Production and sales in-
formation must be provided to 
the FDA, and the company must 
pay a user fee for FDA inspec-
tions. If most large compounders 
opt out, Section 503B will have 
little effect.
If another tragedy similar to 
the one involving the NECC is to 
be avoided, additional action is 
needed. Public health requires 
new legislation in the states, ro-
bust enforcement by the FDA, 
and greater vigilance for patient 
safety by plans and providers.
First, states bear great respon-
sibility for enforcement of com-
pounding quality standards. Al-
though a few states have modified 
rules in the wake of the 2012 fun-
gal meningitis outbreak, most have 
not yet acted.3 In light of the new 
federal law, state legislative re-
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Proposed Massachusetts Reforms.*
Proposed Reform Comments
Unannounced inspections With limited enforcement resources, inspections should be risk-based. Scheduled 
inspections fail to give a representative picture of conditions at the facility.
Mandatory reporting of serious 
adverse events
Federal law and most states do not require reporting of serious adverse events with com-
pounded drugs, although they do require such reporting for other prescription drugs.
Separate licenses for sterile and 
nonsterile compounding based 
on current USP standards
Sterile compounding entails different risks, justifying a more complete regulatory system. 
Most states do not require full compliance with the relevant USP standards.
Transparent reporting of enforce-
ment actions on a public website
Transparency will ensure that all regulators and customers can evaluate quality problems, 
even if they originate in other states, and give compounders a market-based incentive 
to improve.
Whistle-blower protections and 
rewards for employees of 
compounding pharmacies
The best source of information about quality problems is current employees. Under the 
federal False Claims Act, whistle-blowers may qualify for substantial rewards if a 
prosecution is successful.
Mandatory reporting of the volume 
and scope of compounding 
activities
Because registration as an outsourcing facility is voluntary, states should require dis-
closure of the type and number of drugs produced and where they are shipped and 
then share this information with the FDA, to permit the federal government to 
prioritize enforcement resources for the highest-risk compounders.
Disclosures on labels and consent 
forms
Physicians and patients deserve to know that a drug is compounded and whether it was 
produced in an FDA-regulated facility. This information should be on the label and 
clearly described in the patient consent form.
Full license requirements for out- 
of-state compounders shipping 
into Massachusetts
A compounder could avoid the new Massachusetts rules by relocating to a more lightly 
regulated state. With an out-of-state license, all compounding pharmacies selling 
drugs in a given state must meet the same quality standards.
* USP denotes U.S. Pharmacopeial Convention.
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forms are now urgent. Many states 
do not mandate compliance with 
the sterile-compounding require-
ments found in U.S. Pharmaco-
peia Chapter 797. Most states do 
not carefully regulate out-of-state 
compounding pharmacies, nor do 
they systematically share enforce-
ment and inspection reports. The 
FDA and Massachusetts enforce-
ment actions against the NECC 
began in 2004 but were not widely 
reported to other states, and in-
formation about them was not 
transparently available to health 
care providers. If these steps had 
been taken, the NECC might have 
seen reduced sales in out-of-state 
markets, prompting improvements 
in quality control.
Massachusetts accepted pri-
mary regulatory responsibility for 
the NECC tragedy and has spent 
the past year on appropriate re-
sponses, with major reports and 
proposed legislation from both 
the governor and the legisla-
ture.4,5 Since the federal govern-
ment has essentially ceded much 
of the regulatory landscape to 
the states, it is all the more im-
portant to ensure that state regu-
lations meet minimum quality 
standards while not triggering 
drug shortages. Key features of 
the proposed Massachusetts re-
forms are described in the table. 
Each of these reforms plays an 
important role in the quest to 
improve the quality of com-
pounded drugs. For example, the 
out-of-state license is important 
because otherwise a compounder 
like the NECC could avoid the new 
Massachusetts rules by relocating 
to a more lightly regulated state. 
With an out-of-state license, all 
compounding pharmacies selling 
in Massachusetts must meet the 
same quality standards.
Second, the FDA now has 
clearer authority, especially over 
outsourcing facilities, but will be 
successful only if other stake-
holders support the FDA. For ex-
ample, the new law did not pro-
vide any additional budgetary 
appropriations for inspecting com-
pounders that do not register as 
outsourcing facilities. Congress 
needs to adequately fund this 
mission. In addition, registration 
as an outsourcing facility is vol-
untary. For compounders that 
fail to register, the FDA relies on 
states to regulate and share in-
formation.
Finally, rather than being pas-
sive in this process, providers 
and health plans could act to im-
prove the quality and availability 
of compounded drugs. Purchas-
ers can demand that their sterile-
compounded drugs be sourced 
exclusively from outsourcing fa-
cilities regulated by the FDA. 
This decision could also be in-
cluded in accreditation standards 
and reimbursement contracts. 
Such a market-based response 
would force compounders to ac-
cede to their major customers’ 
demands and register with the 
FDA. Alternatively, if providers 
constantly seek out the cheapest 
compounded drugs, then the un-
regulated compounders will have 
an unfair competitive advantage 
and we can expect few com-
pounders to seek FDA approval.
The Drug Quality and Security 
Act may have been a good first 
step, but patients will not be pro-
tected unless states, the FDA, and 
health care providers and plans 
act quickly to fill in the gaps left 
by Congress.
Disclosure forms provided by the author 
are available with the full text of this article 
at NEJM.org.
From Boston University School of Law, Bos-
ton; and the University of Iowa College of 
Law, Iowa City. Professor Outterson was a 
member of the Massachusetts Special Com-
mission on the Oversight of Compounding 
Pharmacies, tasked with proposing respons-
es to the NECC tragedy.
This article was published on December 25, 
2013, at NEJM.org.
1. Testimony of Dr. Lauren Smith, Interim 
Commissioner, Massachusetts Department 
of Public Health. House Committee on 
 Energy and Commerce, Subcommittee on 
Oversight and Investigations, United States 





2. Outterson K. Regulating compounding 
pharmacies after NECC. N Engl J Med 2012; 
367:1969-72.
3. National Conference of State Legislatures. 
State regulation of compounding pharma-
cies. October 2013 (http://www.ncsl.org/ 
research/health/regulating-compounding 
-pharmacies.aspx).
4. Special Commission on the Oversight 
of Compounding Pharmacies. Recommen-
dations on the oversight of compounding 




5. Sánchez J. Pharmaceutical compound-
ing: update on current events and regulatory 
efforts. Massachusetts Legislature Joint Com-





Copyright © 2013 Massachusetts Medical Society.
The Drug Quality and Security Act — Mind the Gaps
The New England Journal of Medicine 
Downloaded from nejm.org on December 25, 2013. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
